FIELD: pharmacology.
SUBSTANCE: invention relates to the salts of 4-((2-(6-(4-methylpiperazine-1-carbonyl)naphthalen-2-yl)ethyl)amino)quinazoline-6-carbonitrile, which have the properties of a cyclin-dependent CDK8/CDK19 kinase inhibitor, and to pharmaceutical compositions comprising these salts, and to the use of such salts or such compositions for treatment of diseases or disorders mediated by the cyclin-dependent CDK8/19 kinase.
EFFECT: new salts are obtained, which have improved solubility compared to the free base.
13 cl, 5 tbl, 23 ex, 5 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| NEW CDK8/19 INHIBITORS | 2018 |
|
RU2763347C2 |
| CDK8/19 INHIBITORS | 2018 |
|
RU2761824C2 |
| NOVEL HETEROCYCLIC COMPOUNDS AS CDK8/19 INHIBITORS | 2018 |
|
RU2739489C2 |
| GLUTAMINE FRUCTOSE-6-PHOSPHATE AMIDOTRANSFERASE INHIBITORS | 2004 |
|
RU2355686C2 |
| NEW CDK8/19 INHIBITORS | 2019 |
|
RU2754441C2 |
| ALKYL [2-(2-{5-[4-(4-{2-[1-(2-METHOXYCARBONYLAMINO-ACETYL)-PYRROLIDIN-2-YL]-3H-IMIDAZOL-4-YL}-PHENYL)-BUTA-1,3-DIINYL]-1H-IMIDAZOL-2-YL}-PYRROLIDIN-1-YL)-2-OXO-ETHYL]-CARBAMATE, PHARMACEUTICAL COMPOSITION, MEDICATION, METHOD OF TREATING VIRAL DISEASES | 2013 |
|
RU2518369C1 |
| 3-(1H-INDOL-3-YL)-4-[2-(4-METHYLPIPERAZIN-1-YL)QUINAZOLIN-4-YL]PYRROLE-2,5-DIONE SALTS | 2008 |
|
RU2487128C2 |
| PHARMACEUTICALLY ACCEPTABLE SALT (E)-N-[4-[[3-CHLORO-4-(2-PYRIDYLMETHOXY) PHENYL] AMINO] -3-CYANO-7-ETHOXY-6-QUINOLYL] -3-[(2R)- 1- METHYLPYRROLIDIN-2-YL] PROP-2-ENAMIDE, METHOD FOR PRODUCTION AND USE THEREOF IN TREATING CANCER | 2012 |
|
RU2583056C2 |
| COMBINATION, INCLUDING A) PYRIMIDYLAMINOBENZAMIDE AND B) KINASE Thr315lle INHIBITOR | 2007 |
|
RU2481840C2 |
| CRYSTALLINE MODIFICATIONS OF 3-(1H-INDOL-3-YL)-4-(4-METHYLPIPERAZIN-1-YL)QUINAZOLIN-4-YL)PYRROL-2,5-DIONE | 2007 |
|
RU2481341C2 |
